Showing results (311-320 of 444) with videos related to
Sort By:
Pageof 45
Journal of Experimental & Clinical Cancer Research : CR|April 7, 2022
Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin IJing Cui, Jingcheng Zhou, Weiqing He, et al.Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.JNCI Cancer Spectrum|March 28, 2025
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping reviewAmanda L King, Tamara Vasilj, Diane Cooper, et al.Neuro-Oncology|March 5, 2008
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesMorris D Groves, Michael J Glantz, Marc C Chamberlain, et al.Neuro-Oncology|June 19, 2008
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor ConsortiumSusan M Chang, Kathleen R Lamborn, John G Kuhn, et al.Neurosurgery|April 5, 2018
Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported OutcomesWilliam A Hall, Stephanie L Pugh, Jeffrey S Wefel, et al.Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.Neuro-Oncology Advances|February 4, 2025
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnosticsKenneth Aldape, David Capper, Andreas von Deimling, et al.Acta Neuropathologica|February 11, 2012
A prognostic gene expression signature in infratentorial ependymomaKhalida Wani, Terri S Armstrong, Elizabeth Vera-Bolanos, et al.Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.Pageof 45